Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 316

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial

Wang, Yongjun, Li, Shuya, Pan, Yuesong, Li, Hao, Parsons, Mark W, Campbell, Bruce C V, Schwamm, Lee H, Fisher, Marc, Che, Fengyuan, Dai, Hongguo, Li, Deyang, Li, Runhui, Wang, Junhai, Wang, Yilong, Zhao, Xingquan, Li, Zixiao, Zheng, Huaguang, Xiong, Yunyun, Meng, Xia, Li, Runhui, Wang, Dong, Wang, Yongjun, Chen, Shengli, Deng, Dan, Zhang, Hong, Wang, Junhai, Chen, Huisheng, Zhang, Hongwei, Wu, Yiping, Liu, Hong, Lu, Guozhi, Zhao, Liandong, Zhu, Runxiu, Liu, Ying, Yi, Fei, Gao, Jianhua, Dai, Hongguo, Hao, Junfang, Che, Fengyuan, Cai, Xueli, Duan, Zhihui, Yu, Hong, Wei, Tongguo, Tang, Yufeng, Peng, Zhaolong, Zhang, Baochao, Song, Yan, Chen, Xiaofei, Liu, Yunlin, Liu, Jing, Li, Deyang, Zhao, Weili, Wei, Xiue, Xue, Qian, Liu, Xuewen, Yang, Yi, zhao, Chuansheng, Chen, Jun, Sui, Yi, Sheng, Guizhi, Zhang, Yun, Liu, Junyan, Zhang, Lianhuan, Wang, Weiwei, Guo, Zhiyong, Li, Hao, Hu, Renping, Chen, Guofang, Liang, Zhigang, Chen, Junbin, Xia, Lei, Long, Zhihua·2023·The Lancet

Abstract

BACKGROUND There is increasing interest in replacing alteplase with tenecteplase as the preferred thrombolytic treatment for patients with acute ischaemic stroke. We aimed to establish the non-inferiority of tenecteplase to alteplase for these patients. METHODS In this multicentre, prospective, open-label, blinded-endpoint, randomised controlled, non-inferiority trial, adults with an acute ischaemic stroke who were eligible for standard intravenous thrombolysis but ineligible for endovascular thrombectomy were enrolled from 53 centres in China and randomly assigned (1:1) to receive intravenous tenecteplase (0·25 mg/kg, maximum dose of 25 mg) or intravenous alteplase (0·9 mg/kg, maximum dose of 90 mg). Participants had to be able to receive treatment within 4·5 h of stroke, have a modified Rankin Scale (mRS) score of no more than 1 before enrolment, and have a National Institutes of Health Stroke Scale score of 5-25. Patients and treating clinicians were not masked to group assignment; clinicians evaluating outcomes were masked to treatment type. The primary efficacy outcome was the proportion of participants who had a mRS score of 0-1 at 90 days, assessed in the modified intention-to-treat population (all randomly assigned participants who received the allocated thrombolytic), with a non-inferiority margin of 0·937 for the risk ratio (RR). The primary safety outcome was symptomatic intracranial haemorrhage within 36 h, assessed in all participants who received study drug and had a safety assessment available. The trial is registered with ClinicalTrials.gov, NCT04797013, and has been completed. FINDINGS Between June 12, 2021, and May 29, 2022, 1430 participants were enrolled and randomly assigned to tenecteplase (n=716) or alteplase (n=714). Six patients assigned to tenecteplase and seven to alteplase did not receive study product, and five participants in the tenecteplase group and 11 in the alteplase group were lost to follow-up at 90 days. The primary outcome in the modified intention-to-treat population occurred in 439 (62%) of 705 in the tenecteplase group versus 405 (58%) of 696 in the alteplase group (RR 1·07, 95% CI 0·98-1·16). The lower limit of the RR's 95% CI was greater than the non-inferiority margin. Symptomatic intracranial haemorrhage within 36 h was observed in 15 (2%) of 711 in the tenecteplase group and 13 (2%) of 706 in the alteplase group (RR 1·18, 95% CI 0·56-2·50). Mortality within 90 days occurred in 46 (7%) individuals in the tenecteplase group versus 35 (5%) in the alteplase group (RR 1·31, 95% CI 0·86-2·01). INTERPRETATION Tenecteplase was non-inferior to alteplase in people with ischaemic stroke who were eligible for standard intravenous thrombolytic but ineligible for or refused endovascular thrombectomy. FUNDING National Science and Technology Major Project, Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences, National Natural Science Foundation of China, and China Shijiazhuang Pharmaceutical Company Recomgen Pharmaceutical (Guangzhou).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(22)02600-9

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Metadata

Authors
Wang, Y., Li, S., Pan, Y., Li, H., Parsons, M. W., Campbell, B. C. V., Schwamm, L. H., Fisher, M., Che, F., Dai, H., Li, D., Li, R., Wang, J., Wang, Y., Zhao, X., Li, Z., Zheng, H., Xiong, Y., Meng, X., Li, R., Wang, D., Wang, Y., Chen, S., Deng, D., Zhang, H., Wang, J., Chen, H., Zhang, H., Wu, Y., Liu, H., Lu, G., Zhao, L., Zhu, R., Liu, Y., Yi, F., Gao, J., Dai, H., Hao, J., Che, F., Cai, X., Duan, Z., Yu, H., Wei, T., Tang, Y., Peng, Z., Zhang, B., Song, Y., Chen, X., Liu, Y., Liu, J., Li, D., Zhao, W., Wei, X., Xue, Q., Liu, X., Yang, Y., zhao, C., Chen, J., Sui, Y., Sheng, G., Zhang, Y., Liu, J., Zhang, L., Wang, W., Guo, Z., Li, H., Hu, R., Chen, G., Liang, Z., Chen, J., Xia, L., & Long, Z.
Venue
The Lancet
Publisher
Elsevier BV
Published
2023-02
Volume
401
Issue
10377
Pages
645-654
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4319663675
Cited by
316
References
23
FWCI
52.85
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial. https://app.cochat.ai/papers/10.1016/s0140-6736(22)02600-9
The paper
Wang, Y., Li, S., Pan, Y., Li, H., Parsons, M. W., Campbell, B. C. V., Schwamm, L. H., Fisher, M., Che, F., Dai, H., Li, D., Li, R., Wang, J., Wang, Y., Zhao, X., Li, Z., Zheng, H., Xiong, Y., Meng, X., . . . Long, Z. (2023). Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial. The Lancet. https://doi.org/10.1016/s0140-6736(22)02600-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.